{"id":1006592,"date":"2026-09-29T10:39:55","date_gmt":"2026-09-29T14:39:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis\/"},"modified":"2026-09-29T10:39:55","modified_gmt":"2026-09-29T14:39:55","slug":"telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis\/","title":{"rendered":"Telitacicept Demonstrates Deep and Durable Minimal Symptom \u00a0Expression Through 48 Weeks in Generalized Myasthenia Gravis"},"content":{"rendered":"
\n

\n More than 94% of participants achieved a \u22655-point MG-ADL improvement at Week 48<\/em>\n <\/p>\n

\n 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks<\/em>\n <\/p>\n

\n After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE <\/em>\n <\/p>\n

\n Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores \u226511 achieved MSE<\/em>\n <\/p>\n

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), evaluating telitacicept in adults with generalized myasthenia gravis (gMG). The findings were presented in an oral presentation during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting in Orlando, Florida.<\/p>\n

The analysis evaluated the depth and durability of clinical response to telitacicept over 48 weeks, including achievement of MSE, defined as a Myasthenia Gravis Activities of Daily Living (MG-ADL) score of 0 or 1. In addition to evaluating whether participants achieved MSE, the analysis assessed whether MSE was sustained at the subsequent monthly assessment and the proportion of remaining follow-up participants spent in MSE after achieving it. The Phase 3 study randomized 114 adults with gMG to telitacicept 240 mg once weekly or placebo for 24 weeks, followed by a 24-week open-label extension (OLE), with those previously on placebo crossing over to telitacicept 240mg. The initial 48-week OLE data were presented at the MGFA Scientific Session at the 2025 AANEM Annual Meeting.<\/p>\n

\u201cOver the past decade, myasthenia gravis has seen meaningful therapeutic innovation, but patients and physicians still live with uncertainty about whether a treatment will work broadly and whether that benefit will last,\u201d said Jean-Paul Kress, M.D., Chairman and Chief Executive Officer of Vor Bio. \u201cWhat stands out in these data are the breadth, depth, and durability of response, with more than 94% of participants achieving at least a five-point improvement in MG-ADL, more than half of those starting with MG-ADL scores of 6-10 reaching MSE, and once MSE was achieved, participants spent the vast majority of their remaining follow-up in that state. If UPSTREAM MG can reproduce this profile globally, we believe telitacicept could give physicians greater confidence in treatment choice and patients greater predictability in how they live their lives.\u201d<\/p>\n

\u201cClinically, reaching MSE once or over a short period is not the same as sustaining that level of disease control over time,\u201d said Richard J. Nowak, M.D., M.S., Director of the Yale Myasthenia Gravis Clinic and Associate Professor of Neurology at Yale School of Medicine. \u201cMyasthenia gravis symptoms can fluctuate over time, so a single assessment provides only a limited window into patient outcomes. These data are encouraging because the response to telitacicept appears to deepen with continued treatment and extends across a broad range of baseline disease severity. As treatment options improve, longitudinal assessment and transparent reporting of MSE durability should become an increasingly important standard so patients and clinicians can better understand not only whether minimal symptoms can be achieved but how consistently they can be maintained.\u201d<\/p>\n

\n Key Findings from the Post Hoc 48-week Analysis:<\/strong>\n <\/p>\n